Drug Trial Radar · NCT04368728
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46,969
Actual
Start
Apr 29, 2020
Primary completion
Feb 10, 2023
Study completion Feb 10, 2023
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Apr 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part. The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate: * As a 2-dose (separated by 21 days) schedule; * At various different dose levels in Phase 1; * As a booster; * In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age \[stratified as 12-15, 16-55 or \>55 years of age\]). The candidate selected for efficacy evaluation in Phase 2/3 is BNT162b2 at a dose of 30 µg. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study. In order to describe the boostability of BNT162, and potential heterologous protection against emerging SARS-CoV-2 VOCs, an additional dose of BNT162b2 at 30 µg will be given to Phase 1 participants approximately 6 to 12 months after their second dose of BNT162b1 or BNT162b2. This will provide an early assessment of the safety of a third dose of BNT162, as well as its immunogenicity. The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a third and potentially a fourth dose of prototype BNT162b2VOC at 30 µg (BNT162b2s01, based upon the South African variant and hereafter referred to as BNT162b2SA). A further subset of Phase 3 participants will receive a third, lower, dose of BNT162b2 at 5 or 10 µg. To further describe potential homologous and heterologous protection against emerging SARS-CoV-2 VOCs, a new cohort of participants will be enrolled who are COVID-19 vaccine-naïve (ie, BNT162b2-naïve) and have not experienced COVID-19. They will receive BNT162b2SA given as a 2-dose series, separated by 21 days. To reflect current and anticipated recommendations for COVID 19 vaccine boosters, participants in C4591001 who meet specified recommendations and have not already received one, will be offered a third dose of BNT162b2 after their second dose of BNT162.
Conditions
- SARS-CoV-2 Infection
- COVID-19
Interventions
BNT162b1Biological
Intramuscular injection
BNT162b2Biological
Intramuscular injection
PlaceboOther
Intramuscular injection
BNT162b2SABiological
Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1Time frame: Within 7 days after Dose 1
- Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 1Time frame: Within 7 days after Dose 2
- Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 1Time frame: Within 7 days after Dose 1
- Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 1Time frame: Within 7 days after Dose 2
- Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 1Time frame: From Dose 1 to 1 Month After Dose 2
- Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 1Time frame: From Dose 1 to 6 Months After Dose 2
- Percentage of Participants With Abnormalities in Hematology Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
- Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
- Percentage of Participants With Abnormalities in Hematology Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
- Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
- Percentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
- Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
- Percentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
- Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
- Percentage of Participants With Grade Shift in Hematology Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
- Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
- Percentage of Participants With Grade Shift in Hematology Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
- Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
- Percentage of Participants With Grade Shift in Chemistry Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
- Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
- Percentage of Participants With Grade Shift in Chemistry Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
- Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
- Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2/3Time frame: Within 7 Days after Dose 1
- Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2/3Time frame: Within 7 Days after Dose 2
- Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2/3Time frame: Within 7 Days after Dose 1
- Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2/3Time frame: Within 7 Days after Dose 2
- Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/3Time frame: From Dose 1 to 1 Month After Dose 2
- Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/3Time frame: From Dose 1 to 6 Months After Dose 2
- Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2Time frame: Within 7 Days after Dose 1
- Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2Time frame: Within 7 Days after Dose 2
- Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2Time frame: Within 7 Days after Dose 1
- Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2Time frame: Within 7 Days After Dose 2
- Percentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2Time frame: From Dose 1 to 7 Days After Dose 2
- Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2Time frame: From Dose 1 to 7 Days After Dose 2
- Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: Within 7 Days After Booster Dose
- Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: Within 7 Days After Booster Dose
- Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: From First Booster Dose to 1 Month After Booster Dose
- Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: From First Booster Dose to 6 Months After Booster Dose
- Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days After Booster Dose 1
- Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days after Booster Dose 2
- Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days After Booster Dose 1
- Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days After Booster Dose 2
- Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: From First Booster Dose to 1 Month After Second Booster Dose
- Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: From First Booster Dose to 5 Months After Second Booster Dose
- Percentage of Participants With Local Reactions Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 1
- Percentage of Participants With Local Reactions Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 2
- Percentage of Participants With Systemic Events Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 1
- Percentage of Participants With Systemic Events Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 2
- Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SATime frame: From Dose 1 Through 1 Month After Dose 2
- Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SATime frame: From Dose 1 to 6 Months After Dose 2
- Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: Within 7 days After Booster Dose
- Percentage of Participants With Systemic Events Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: Within 7 days After Booster Dose
- Percentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: From Booster Dose to 1 Months After Booster Dose
- Percentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: From Booster Dose to 6 Months after Booster Dose
- COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.247, Placebo - 6.003)
- COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.214, Placebo - 2.222)
- COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.509, Placebo - 6.274)
- COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.332, Placebo - 2.345)
- GMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 3Time frame: 1 Month After Dose 2
- Percentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3Time frame: 1 Month After Dose 2
- GMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
- Percentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
- GMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
- Percentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
Locations
175 sites in 6 countries. Site status is shown where the registry gives one.
North Alabama Research Center, LLC
Athens, Alabama
Birmingham Clinical Research Unit
Birmingham, Alabama
Medical Affiliated Research Center
Huntsville, Alabama
Optimal Research, LLC
Huntsville, Alabama
Alliance for Multispecialty Research, LLC
Mobile, Alabama
Chinle Comprehensive Health Care Facility
Chinle, Arizona
Johns Hopkins Center for American Indian Health
Chinle, Arizona
HOPE Research Institute
Phoenix, Arizona
The Pain Center of Arizona
Phoenix, Arizona
HOPE Research Institute
Phoenix, Arizona
Alliance for Multispecialty Research, LLC
Tempe, Arizona
Johns Hopkins Center for American Indian Health
Whiteriver, Arizona
Whiteriver Indian Hospital - Garrett Building
Whiteriver, Arizona
Whiteriver Indian Hospital
Whiteriver, Arizona
Anaheim Clinical Trials, LLC
Anaheim, California
Collaborative Neuroscience Research, LLC. - Investigator Site File Location
Garden Grove, California
Collaborative Neuroscience Research, LLC
Long Beach, California
Long Beach Clinical Trials Services Inc.
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
National Research Institute
Los Angeles, California
Velocity Clinical Research, North Hollywood
North Hollywood, California
Paradigm Clinical Research Center
Redding, California
Kaiser Permanente Sacramento
Sacramento, California
Clinical and Translational Science Center (CTSC) Clinical Research Center (CCRC)
Sacramento, California
University of California Davis Health
Sacramento, California
California Research Foundation
San Diego, California
Kaiser Permanente Santa Clara
Santa Clara, California
Bayview Research Group
Valley Village, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Lynn Institute of Denver
Aurora, Colorado
Clinical Research Consulting, LLC
Milford, Connecticut
Yale University
New Haven, Connecticut
Yale Center for Clinical Investigations (CSRU)
New Haven, Connecticut
Alliance for Multispecialty Research
Coral Gables, Florida
DeLand Clinical Research Unit
DeLand, Florida
Fleming Island Center for Clinical Research
Fleming Island, Florida
Indago Research & Health Center, Inc
Hialeah, Florida
Research Centers of America
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.